Shuttle Pharma On Pace To Enroll Patients In Phase 2 Clinical Trial Of Ropidoxuridine For Treatment Of Glioblastoma
Portfolio Pulse from Benzinga Newsdesk
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) announced the initiation of a Phase 2 clinical trial for Ropidoxuridine, a radiation sensitizer, for the treatment of glioblastoma. The trial will enroll 40 patients to determine the optimal dose and aims to improve survival rates for this aggressive brain tumor.
August 14, 2024 | 8:38 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) has initiated a Phase 2 clinical trial for Ropidoxuridine, targeting glioblastoma. The trial aims to determine the optimal dose and improve survival rates for this aggressive brain tumor.
The initiation of a Phase 2 clinical trial for Ropidoxuridine is a significant milestone for Shuttle Pharma. Positive results could lead to FDA approval and market exclusivity, potentially boosting the company's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100